Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Agonists of the microprotein BRAWNIN in the treatment of Charcot Marie Tooth disease

Project description

Increasing BRAWNIN protein use to treat neurodegenerative diseases

Advancements in digital technologies, neurology, biology, and medicine have greatly enhanced our understanding of the nervous system, its functions, and its associated diseases. Increasing evidence highlights the critical role of mitochondria and metabolic regulation in nervous system function, with mitochondria playing a key role in maintaining cellular metabolic homeostasis. The BRAWNIN protein is vital for regulating mitochondrial function in neurons. The ERC-funded ABC-MT project aims to develop a gene-therapy strategy to increase the presence of the BRAWNIN protein, offering protective and therapeutic benefits for patients with axonal metabolic diseases. The project underscores the impact of metabolic deregulation on axons and its connection to neurodegenerative diseases.

Objective

This project will provide proof of concept for the neuroprotective potential of agonists of the mitochondrial protein BRAWNIN. We have identified that BRAWNIN is an important regulator of mitochondrial function in neurons. Mitochondria are essential organelles to support metabolic homeostasis in the cell. Mounting evidence in the literature demonstrate that mitochondria and more broadly metabolic regulation is central to the function of the nervous system. Axons are especially affected by metabolic deregulation, which can lead to axonal degeneration. In this application, we propose that increasing the cellular levels of protein BRAWNIN using a gene-therapy strategy (defined as BRAWNIN agonists) will be protective in neurodegenerative disease, and we will demonstrate this in models of Charcot Marie Tooth disease, a peripheral neuropathy strongly associated with altered metabolism and mitochondria. Overall, our project will provide the first demonstration that BRAWNIN is a target of therapeutic interest in axonal metabolic diseases, which we will further develop with the ultimate goal to develop BRAWNIN agonists for patients.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 150 000,00
Address
RUE DE TOLBIAC 101
75654 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)